Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Jan 6.

Published in final edited form as: Open Diabetes J. 2012;5:1–7. doi: 10.2174/1876524601205010001

Fig. 5 — Fig. (5A). The mean (+ SEM) staining intensity of glucose transporter 3 (GluT3) immunoreactivity (quantified by thresholded pixels) within the medial prefrontal cortex (mPFC) at the end of Set-Shift testing in control animals (CTL) and in animals induced with recurrent bouts of hypoglycemia on each of preceding 3 days of testing (RH). No significant differences were observed in the mean staining intensity of GluT3 between the treatment groups.

Fig. (5B). A representative medial prefrontal cortex (mPFC) GluT3 immunostaining from CTL and RH animals. Bar = 10μm.

Fig. 5 — Fig. (5A). The mean (+ SEM) staining intensity of glucose transporter 3 (GluT3) immunoreactivity (quantified by thresholded pixels) within the medial prefrontal cortex (mPFC) at the end of Set-Shift testing in control animals (CTL) and in animals induced with recurrent bouts of hypoglycemia on each of preceding 3 days of testing (RH). No significant differences were observed in the mean staining intensity of GluT3 between the treatment groups.

Fig. (5B). A representative medial prefrontal cortex (mPFC) GluT3 immunostaining from CTL and RH animals. Bar = 10μm.